Efficacy and Safety Study to Evaluate SD-101 in Epidermolysis Bullosa
NCT07482787
·
clinicaltrials.gov ↗
PHASE3
Phase
NOT_YET_RECRUITING
Status
80
Enrollment
INDUSTRY
Sponsor class
Conditions
Epidermolysis Bullosa (EB)
Interventions
DRUG:
SD-101 Dermal Cream (6%)
DRUG:
Vehicle (SD-101 0%)
Sponsor
Paradigm Therapeutics